^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    setanaxib (GKT831)

    i
    Other names: GKT831, GKT-137831, GKT137831, GKT 137831, GKT-831, GKT 831
    Associations

    News

    Trials
    Company:
    Calliditas, National Institutes of Health
    Drug class:
    NOX1 inhibitor, NOX4 inhibitor
    Associations

    News

    Trials
    3ms
    GSN000400: A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (clinicaltrials.gov)
    P2, N=55, Completed, Calliditas Therapeutics Suisse SA | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • setanaxib (GKT831)
    5ms
    A Study to Evaluate Setanaxib in Patients With Alport Syndrome (clinicaltrials.gov)
    P1/2, N=19, Completed, Calliditas Therapeutics AB | Active, not recruiting --> Completed
    Trial completion
    |
    setanaxib (GKT831)
    10ms
    Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria (clinicaltrials.gov)
    P2, N=136, Completed, Calliditas Therapeutics AB | N=200 --> 136
    Enrollment change
    |
    setanaxib (GKT831)
    10ms
    A Study to Evaluate Setanaxib in Patients With Alport Syndrome (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Calliditas Therapeutics AB | Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> May 2025
    Trial completion date • Trial primary completion date
    |
    setanaxib (GKT831)
    10ms
    A Study to Evaluate Setanaxib in Patients With Alport Syndrome (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Calliditas Therapeutics AB | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    setanaxib (GKT831)
    1year
    GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis (clinicaltrials.gov)
    P2, N=58, Completed, University of Alabama at Birmingham | Recruiting --> Completed
    Trial completion
    |
    setanaxib (GKT831)
    over1year
    A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Calliditas Therapeutics Suisse SA | Trial completion date: Sep 2024 --> Nov 2025
    Trial completion date • Metastases
    |
    Keytruda (pembrolizumab) • setanaxib (GKT831)
    over1year
    TRANSFORM: A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (clinicaltrials.gov)
    P2, N=76, Completed, Calliditas Therapeutics Suisse SA | Active, not recruiting --> Completed
    Trial completion
    |
    setanaxib (GKT831)
    over1year
    Particulate Matter-Induced Neurotoxicity: Unveiling the Role of NOX4-Mediated ROS Production and Mitochondrial Dysfunction in Neuronal Apoptosis. (PubMed, Int J Mol Sci)
    The cytotoxic effects induced by PMs were alleviated by NOX inhibitors GKT137831 and Apocynin...Variability in NADPH oxidase sources underscores the complexity of PM-induced neurotoxicity. Our findings highlight NOX4-driven ROS and mitochondrial dysfunction, suggesting a potential therapeutic approach for mitigating PM-induced neurotoxicity.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • NOX4 (NADPH Oxidase 4) • VDAC1 (Voltage Dependent Anion Channel 1)
    |
    setanaxib (GKT831)
    over1year
    A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Calliditas Therapeutics Suisse SA | Trial completion date: Jun 2024 --> Sep 2024
    Trial completion date • Metastases
    |
    Keytruda (pembrolizumab) • setanaxib (GKT831)
    over1year
    GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov)
    P2, N=60, Recruiting, University of Alabama at Birmingham | Trial completion date: Apr 2024 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Nov 2024
    Trial completion date • Trial primary completion date
    |
    setanaxib (GKT831)
    almost2years
    TRANSFORM: A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Calliditas Therapeutics Suisse SA | Recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | N=318 --> 70 | Trial completion date: Sep 2025 --> Jul 2024
    Enrollment closed • Phase classification • Enrollment change • Trial completion date
    |
    setanaxib (GKT831)